WHY WAS THIS FUNDED?

This award appears to be part of the federal government's medical countermeasure programs, which prepare the country to respond to large-scale emergencies such as nuclear incidents, biological attacks, or other mass casualty events. These programs are typically authorized under laws like the Pandemic and All-Hazards Preparedness Act, which directs the government to stockpile and develop emergency medical treatments.

WHAT PUBLIC PROBLEM IS IT TRYING TO SOLVE?

In a mass casualty event, such as a nuclear explosion or a large-scale radiation accident, many people can suffer severe drops in their platelet counts, which are the blood cells that help wounds clot and stop bleeding. Without treatment, these individuals face a high risk of uncontrolled bleeding and death, and this contract is meant to ensure a treatment is available if such an emergency ever occurs.

WHO BENEFITS?

American civilians and military personnel who might be exposed to radiation or other threats that destroy platelets in a large-scale emergency would be the primary beneficiaries. Amgen employees involved in research, manufacturing, and distribution of the treatment also benefit through employment supported by this contract.

WHAT ARE THE RISKS?

A ten-year, single-company contract of this size carries risks around accountability, including whether the government is getting a fair price and whether Amgen will deliver a fully effective product on schedule. There is also the risk that the treatment may never be needed if no mass casualty event occurs, meaning taxpayer funds would be spent on a product held in reserve.

WHAT HAPPENS IF FUNDING IS REMOVED?

If this contract were cancelled, the government would lose progress toward having a ready treatment for platelet loss in mass casualty events, leaving a potential gap in emergency medical preparedness. In the event of a large-scale radiation emergency or similar disaster, medical responders might not have an approved, stockpiled treatment available to save lives.

ARGUMENTS FOR

• •Investing in emergency medical treatments before a disaster strikes is far less costly than trying to develop them during a crisis, when time is critical and lives are at stake.
• •Having a stockpiled treatment for mass casualty events strengthens national security and protects both civilians and military personnel from threats like nuclear incidents or radiological attacks.
• •Long-term contracts give pharmaceutical companies the financial certainty they need to invest in research and manufacturing for treatments that would otherwise have very limited commercial markets.

ARGUMENTS AGAINST

• •Nearly 840 million dollars is a very large sum for a treatment that may never be used, raising questions about whether these funds could be better spent on more immediate public health needs.
• •Awarding a long-term contract to a single large company limits competition, which can reduce pressure to keep prices fair and performance high.
• •Without detailed public reporting on milestones and deliverables, it can be difficult for taxpayers and lawmakers to verify that the money is being spent effectively over the ten-year period.